Author: Lynne Taylor

Many of Europe’s nearly 2 million rheumatoid arthritis patients are still unable to access effective new biologic treatments, and whether they can do so or not is largely dependent on where they live, says a new study.

The United States Patent and Trademark Office (USPTO) has announced that four controversial patent regulations, which GlaxoSmithKline (GSK) has fought in the courts, have been dropped.

Patients are ready to accept much higher levels of risk than medical experts believe, if the benefit of a treatment is clearly described and likely to happen, according to a leading patients group.

The European Commission must reconsider its veto of initiatives undertaken by GlaxoSmithKline (GSK) in Spain to combat parallel importing, the European Court of Justice (ECJ) ruled yesterday.

The European Medicines Agency (EMEA) announced yesterday that it has begun a series of changes to its internal organisation, aimed at improving its functioning and how it delivers its core tasks to be introduced gradually by year-end.